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Comparison of Inhibitory and Bactericidal
Activities of Cefoperazone + Sulbactam Against
Pseudomonas aeruginosa Strains, from 1992 to
1994
Abstract: In this study; inhibitory and
bactericidal activities of cefoperazone +
sulbactam against Pseudomonas aeruginosa
strains were determined in two studies first
in 1992 and second in 1994. Minimum
inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) values were
determined by following the microdilution
method recommended by NCCLS (Approved
Standard
M7-A2
1990)
protocol.
P.aeruginosa strains were isolated from
different clinical materials. The results of the
studies were then compared to point out if
the difference between MIC and MBC values
were significant and if there was resistance
development following two years of use. In
the first study in 1992: MIC90 and
susceptibility percentage were 8 µgr/ml and
99%; MBC90 and susceptibility percentage
were 64 µg/ml and 90%, respectively. In the
second study: MIC90 was 128 µg/ml;
susceptibility percentage was 71%; MBC90

Introduction
Cefoperazone+sulbactam is an effective agent against
Pseudomonas aeruginosa which is one of the most common cause of nosocomial infections particularly in
patients with impaired defence mechanisms who therefore require bactericidal rather than bacteriostatic therapy (1,2).
The antimicrobial susceptibility of bacteria is in general evaluated by the relationship between minimum
inhibitory concentration (MIC) and the blood level of the
drug. This evaluation considers only the bacteriostatic
activity of the drug and assumes that minimum bactericidal concentration (MBC) does not differ from MIC significantly which is principally acceptable for bactericidal
antibiotics (3).
In this study; the inhibitory and the bactericidal activities of cefoperazone+sulbactam against P.aeruginosa
strains were determined in two studies first in 1992 and
second in 1994. The results of the studies were then
compared in order to point out if the difference between

and susceptibility percentage were 256 µg/ml
and 28%, respectively. When the
susceptibilities were compared according to
MIC90 and MBC90 values; the difference was
not significant in 1992 (χ2= 0.43, p>0.05),
but significant in 1994 (χ2= 18.8, p<0.001).
The difference between the susceptibilities
according to MIC90 values was statistically
significant (χ2= 4.6, p<0.05), where
according to MBC90 values very significant
(χ2= 32.56, p<0.001). These results
indicated that the antipseudomonal activity of
cefoperazone+sulbactam reduced since 1992
to 1994 and MBC determinations were
necessary to evaluate the antibiotic
susceptibility of P.aeruginosa rather than
MIC determinations.
Key Words: Pseudomonas aeruginosa,
cefoperazone+sulbactam,
MIC,
MBC,
susceptibility determination.

inhibitory and bactericidal activities were significant and if
there was resistance development following two years of
use.
Materials and Methods
Each year, 100 P.aeruginosa strains, isolated from
various clinical materials were identified by conventional
methods and confirmed by API 20NE (bioMerieux) in the
Microbiology Laboratory of Refik Saydam Hygiene
Center. The MIC and MBC values of these strains were
determined by standard methods recommended by
NCCLS (Approved Standard M7-A3,1993) (4).
The antimicrobial powder with known potence was
obtained from the pharmaceutical manufacturer. Stock
solutions of the antimicrobial were prepared in MuellerHinton broth (MHB) (Oxoid) and used on the day of testing and kept frozen at -70°C for maximum 15 days (4).
MHB was used in the microdilution method. Antibiotic
solution was dispensed in the first well and serially diluted within the wells of disposable plastic U-shaped
microtiter plates obtaining 50 µg/well. Suspensions of the
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test organisms were prepared by 1:1000 dilution of
overnight cultures. The suspensions were dispensed in
50µl volumes into the antibiotic containing wells. The
ranges were arranged between 256-0.125. The final
inoculum concentration was about 5x105 cfu/ml. The
plates were incubated overnight at 37°C (4).
The MIC was defined as the lowest concentration of
the antibiotic that inhibited the growth of the organism as
detected by lack of visual turbidity. All the wells that had
no turbidity and the last well with turbidity were subcultured to sheep blood agar as 10µl and incubated at 37°C
for 24 hours. The colonies of P.aeruginosa were counted
in order to determine the MBC values which were defined
as the lowest concentration of the antibiotic that allowed
more than 99.9% of the original inoculum devitalization
(4).
According to NCCLS breakpoints, including the moderate susceptibilities, ≤16µg/ml were susceptible,
≥64µg/ml were resistant. The combination of sulbactam
and cefoperazone were 1:1. P.aeruginosa ATCC 27853
was included in each test as reference strain (4).
Results
The activity of cefoperazone+sulbactam against
P.aeruginosa strains were evaluated by means of MIC,
MBC values and the susceptibility percentages of the
agent in two studies in 1992 and 1994 on the table.
When the susceptibilities were compared according to
MIC90 and MBC90 values; the difference was not significant in 1992 (χ2 = 0.43, p>0.05), but significant in
1994 (χ2 = 18.8, p<0.001). The difference between the
susceptibilities according to MIC90 values between two
years 1992 and 1994 were statistically significant (χ2 =
4.6, p<0.05). The difference between the susceptibilities
according to MBC90 values between two years 1992 and
1994 were statistically very significant (χ2 = 32.56,
p<0.001).
Discussion
Cefoperazone is a third generation cephalosporin that
has a wide antibacterial spectrum. As a beta-lactam
Table:

P.aeruginosa
Years
1992
1994
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antibiotic; it should penetrate through the bacterial cell
wall, be resistant to beta-lactamase enzymes and bind to
the penicillin binding proteins. When cefoperazone is
combined with a beta-lactamase inhibitor like sulbactam,
its in vitro activity increases. This combination is found to
be effective against P.aeruginosa strains (1). For an
antibiotic to have a particular effectiveness against a
species, at least 50% of the strains should have MIC values below the mean concentrations attained at the site of
infection or in the blood (3).
In 1992, we determined that P.aeruginosa strains
were susceptible to cefoperazone+sulbactam with MIC
and MBC values which were similar with the other studies of that year in our country (5,6). In 1994, it was susceptible with MIC but resistant with MBC values that
made it difficult to be qualified as an effective
antipseudomonal antibiotic. Therefore if MIC would be
taken as the reference point for the laboratory designations “susceptible or resistant”, MBC determinations
would be more certain for the prediction of susceptibility
in the cases that required bactericidal therapy rather than
bacteriostatic therapy such as impaired defence mechanisms were there (7,8).
In the first study in 1992, the susceptibility was very
high, because it was the first year that cefoperazone+sulbactam was commercialy available in our country.
However, using the same breakpoints it gave a very different susceptibility pattern in 1994. Especially when
MBC values were considered, it was obvious that the
spectrum of activity reduced against P.aeruginosa.
Resistance rates for two different periods were significantly different and higher in the second year. We had
observed the resistance development against cefoperazone+sulbactam in two years’ time (9).
The data indicated that MBC determinations were necessary to evaluate the antibiotic susceptibility of P.aeruginosa rather than MIC determinations at least in patients
with impaired defence mechanisms which required bactericidal therapy. It was also indicated that there was resistance development against cefoperazone+sulbactam
among P.aeruginosa since 1992 to 1994 because of the
uncontrolled wide usage of the antibiotic.

MIC90, MBC90 and susceptibility percentages of cefaperazone+sulbactam against P.aeruginosa strains in 1992 and 1994
(n=100)
Ranges
0.125-256
0.125-256

MIC
90
8
128

Susceptibility %
99%
71%

MBC
90
64
256

Susceptibility %
90%
28%
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